VKTX
Income statement / Annual
Last year (2024), Viking Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Viking Therapeutics, Inc.'s net income was -$109.96 M.
See Viking Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$260.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$260.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$101.64 M
|
$63.81 M
|
$54.23 M
|
$44.98 M
|
$31.93 M
|
$23.56 M
|
$19.04 M
|
$13.74 M
|
$9.00 M
|
$6.97 M
|
| General & Administrative Expenses |
$49.28 M
|
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$0.00
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
$5.03 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.28 M
|
$37.02 M
|
$16.12 M
|
$10.70 M
|
$10.73 M
|
$8.87 M
|
$7.12 M
|
$5.33 M
|
$4.85 M
|
$5.03 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$150.92 M
|
$100.83 M
|
$70.36 M
|
$55.68 M
|
$42.66 M
|
$32.43 M
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
$12.00 M
|
| Cost And Expenses |
$150.92 M
|
$100.83 M
|
$70.36 M
|
$55.68 M
|
$42.66 M
|
$32.69 M
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
$12.00 M
|
| Interest Income |
$40.94 M
|
$15.02 M
|
$1.59 M
|
$703.00 K
|
$3.23 M
|
$7.05 M
|
$3.24 M
|
$1.27 K
|
$0.00
|
$0.00
|
| Interest Expense |
$94.00 K
|
$88.00 K
|
$0.00
|
$18.00 K
|
$106.00 K
|
$146.00 K
|
$404.00 K
|
$1.28 M
|
$1.81 M
|
$982.18 K
|
| Depreciation & Amortization |
$346.00 K
|
$292.00 K
|
$291.00 K
|
$296.00 K
|
$277.00 K
|
$260.00 K
|
$26.16 M
|
$19.07 M
|
$13.85 M
|
-$10.43 M
|
| EBITDA |
-$150.58 M |
-$100.54 M |
-$70.06 M |
-$55.39 M |
-$39.11 M |
-$25.37 M |
$4.66 M |
$442.88 K |
$1.15 M |
-$22.39 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$40.96 M
|
$14.93 M
|
$1.49 M
|
$692.00 K
|
$3.17 M
|
$6.91 M
|
$4.10 M
|
-$1.51 M
|
-$884.55 K
|
-$11.41 M
|
| Income Before Tax |
-$109.96 M
|
-$85.90 M
|
-$68.87 M
|
-$54.99 M
|
-$39.50 M
|
-$25.78 M
|
-$22.06 M
|
-$20.58 M
|
-$14.73 M
|
-$23.40 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$109.96 M
|
-$85.90 M
|
-$68.87 M
|
-$54.99 M
|
-$39.50 M
|
-$25.78 M
|
-$22.06 M
|
-$20.58 M
|
-$14.73 M
|
-$23.40 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.01 |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
-3.68 |
| EPS Diluted |
-1.01 |
-0.91 |
-0.88 |
-0.7 |
-0.5 |
-0.36 |
-0.38 |
-0.79 |
-0.9 |
-3.68 |
| Weighted Average Shares Out |
$109.04 M
|
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
$6.36 M
|
| Weighted Average Shares Out Diluted |
$109.04 M
|
$94.35 M
|
$76.83 M
|
$77.20 M
|
$72.60 M
|
$71.96 M
|
$57.58 M
|
$25.98 M
|
$16.28 M
|
$6.36 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
